Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-12-23
2008-08-19
Crouch, Deborah (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07414032
ABSTRACT:
The present invention relates to a DNA vaccine for developing tumor-specific immunity. Specifically, the invention relates to a DNA vaccine comprising antigens recognized by CD4+helper T cells and CD8+cytotoxic T cells, respectively. Preferably, the antigen recognized by CD4+helper T cells is a molecule identified by the SEREX method and that recognized by CD8+cytotoxic T cells is a tumor-specific antigen, tumor-associated antigen or cell-associated antigen. Furthermore, so that the antigens recognized by CD4+helper T cells and CD8+CTL are expressed and presented on the same cell, the expression vectors preferably are immobilized on the same gold particle and administered into the cell by gene gun; however, this invention is not restricted thereto. The vaccine can also be used as a pharmaceutical agent.
REFERENCES:
patent: 6194389 (2001-02-01), Johnston et al.
patent: 2003/0092162 (2003-05-01), Shankara et al.
patent: 2000-302692 (2000-10-01), None
patent: WO 00/34494 (2000-06-01), None
patent: WO 00/40752 (2000-07-01), None
patent: WO 00/40752 (2000-07-01), None
patent: WO 01/53524 (2001-07-01), None
patent: WO 01/53524 (2001-07-01), None
patent: WO 01/83750 (2001-11-01), None
patent: WO 01/83750 (2001-11-01), None
Resitfo et al. (2000) The Promise of nucleic acid vaccines. Gene Therapy. 7:89-92.
McCluskie et al. (1999) Route and Method of Delivery of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates. Molecular Medicine. 5:287-300.
Verma et al., Gene therapy-promises, problems and prospects. (1997) Nature. 389:239-242.
Orkin et al., Report and Reccommendations of the Panel to assess the NIH invextment in Research on Gene Therapy (1998) 1-41.
Marshall., Gene Therapy's Growing Pains (1995) Science 269:1050-1055.
Tuting et al. (1998) Co-Delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice:studies with the model tumor antigen Beta-galactosidase and the BALB/c Meth A p53 tumor specfic antigen. Gene Therapy 6:629-636.
Ulmer et al. (1998) Protective CD4+ and Cd8+ T cells against Influenza Virus Induced by Vacination with Nucleoprotein DNA. Journal of Virology 72:5648-5653.
Chen et al. (2000) Clinical Cancer Research 6 :4381-4388.
Gnjatic et al. (2000) PNAS 97 :10917-10922.
Hanke et al. (1999) Vaccine 589-596.
Gnjatic et al. Strategy for Monitoring T Cell Responses to NY-ESO-1 in Patients with any HLA Class I Allele. PNAS, 2000, vol. 97, No. 20, pp. 10917-10922.
Chen et al. Induction of Antitumor Immunity with Combination of HER2
eu DNA Vaccine and Interleukin 2 Gene-Modified Turmo Vaccine. Clinical Cancer Res., 2000, vol. 6, pp. 4381-4388.
Nomura et al. Gene Expression and Antitumor Effects Following Direct Interferon Gamma Gene Transfer with Naked Plasmid DNA and DC-Chol Liposome Complexes in Mice. Gene Therapy, 1999, vol. 6, pp. 121-129.
Ikeda Hiroaki et al.; “Mutated mitogen-activated protein kinase: A tumor rejection antigen of mouse sarcoma”;Proc. Nat'l. Acad. Sci. U.S.A.; Jun. 1997; pp. 6375-6379; vol. 94.
Nishikawa, Hiroyoshi et al.; “Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity”;PNAS; Dec. 4, 2001; pp. 14571-14576; vol. 98, No. 25.
Nishikawa, Hiroyoshi et al.;Clinical Immunology(translation); 2002; pp. 328-333; vol. 37, No. 3; Japan (in Japanese).
Shiku, Hiroshi;Gendai Iryo; 2000; pp. 24-30; vol. 32, No. 5; Japan (in Japanese).
Shiku, Hiroshi; “Peptide vaccine for cancer”;Tissue Culture(translation); 2000; pp. 9-12; vol. 26, No. 1; Japan (in Japanese).
Liu, M.A.; “DNA vaccines: a review”;Journal of Internal Medicine253:402-410 (2003).
Roy, Michael J. et al.; “Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of hepatitis 8 virus DNA vaccine”;Vaccine19:764-778 (2001).
Shiku, Hiroshi et al.; “Development of a cancer vaccine: peptides, proteins, and DNA”;Cancer Chemother. Pharmacol.; 2000; pp. S77-S82; vol. 46(Suppl.); Springer Verlag.
Swain, W. F.; “Tolerability and Immune Responses in Humans to a PowderJect DNA Vaccine for Hepatits B”;Dev. Biol. 104:115-119 (2000).
Kim, Jong J. et al.; “Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine”;Oncogene; 1998; pp. 3125-3135; vol. 17; Stockton Press.
King, Catherine A. et al.; “DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma”;Nature Medicine; Nov. 1998; pp. 1281-1286; vol. 4, No. 11.
Lachman, Lawrence B. et al.; “DNA vaccination againstneureduces breast cancer incidence and metastasis in mice”;Cancer Gene Therapy; 2001; pp. 259-268; vol. 8, No. 4; Nature Publishing Group.
Sahin, Ugur et al.; “Human neoplasms elicit multiple specific immune responses in the autologous host”;Proc. Natl. Acad. Sci. U.S.A.; Dec. 1995; pp. 11810-11813; vol. 92.
Shiku, Hiroshi er al.; “Development of a cancer vaccine: peptides, proteins, and DNA”;Cancer Chemother. Pharmacol.; 2000; pp. S77-S72; vol. 46 (Suppl.); Springer-Verlag.
Takeda, Junko et al.; “Anti-tumor immunity against CT26 colon tumor mice immunized with plasmid DNA encoding β-galactosidase fused to an envelope protein of endogenous retrovirus”;Cellular Immunology; 2000; pp. 11-18; vol. 204; Academic Press.
Velders, Markwin P. et al.; “Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine”;The Journal of Immunology; 2001; pp. 5366-5373; vol. 166.
Chen, Y.T. et al.; 1997,Proceedings of the National Academy of Sciences, vol. 94, No. 5, pp. 1914-1918.
Jaeger, E., et al.; 2000,Proceedings of the National Academy of Sciences, vol. 97, No. 22, pp. 12198-12203.
Jaeger, E. et al.; 2001, Breast, pp. 158-160.
Crouch Deborah
Immunofrontier, Inc.
Townsend and Townsend / and Crew LLP
LandOfFree
Vaccine comprising a polynucleotide encoding an antigen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine comprising a polynucleotide encoding an antigen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine comprising a polynucleotide encoding an antigen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4005067